Skip to main content
SpringerLink
Log in

Management of Newly Diagnosed Metastatic Disease

  • Chapter
  • First Online:
Management of Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 1435 Accesses

Abstract

Prostate cancer (CaP) is a common disease with an incidence of approximately 192,280 cases in 2009, with an estimated 27,360 deaths. The great majority of men who present with CaP will be diagnosed with locally confined disease, with de novo metastatic CaP only occurring around 4 % of the time in 2009. This finding is dramatically different than in the pre-PSA era in which a substantially greater portion presented with metastatic disease. This stage migration which has occurred over the last 20 years is due largely to the incorporation of PSA testing into CaP. Since 2001, the incidence of CaP has been declining at a rate of about 4.4 % which also coincides with increased public awareness and utilization of effective screening approaches. Unfortunately, despite our increasing understanding of CaP biology, metastatic CaP remains a uniformly fatal disease. Additionally, approximately 30–40 % of men who undergo therapy for local disease will subsequently develop metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.

    PubMed  Google Scholar 

  2. Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol. 1997;15(6):331–5.

    PubMed  CAS  Google Scholar 

  3. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996;276(16):1309–15.

    PubMed  CAS  Google Scholar 

  4. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000;164(1):101–5.

    PubMed  CAS  Google Scholar 

  5. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24(2): 395–406.

    PubMed  CAS  Google Scholar 

  6. Laufer M, Pound CR, Carducci MA, Eisenberger MA. Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology. 2000;55(3):309–15.

    PubMed  CAS  Google Scholar 

  7. Dillioglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997;50(1):93–9.

    PubMed  CAS  Google Scholar 

  8. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.

    PubMed  CAS  Google Scholar 

  9. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.

    CAS  Google Scholar 

  10. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5(5):545–57.

    PubMed  CAS  Google Scholar 

  11. Huggins C, Hodges CV. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209.

    CAS  Google Scholar 

  12. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer. III. The effects of fever, of desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J Urol. 1941;46:997.

    CAS  Google Scholar 

  13. Schellhammer PF. Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology. 1996;47(5):622–8.

    PubMed  CAS  Google Scholar 

  14. Peeling WB, Phase III. studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology. 1989;33(5 Suppl):45–52.

    PubMed  CAS  Google Scholar 

  15. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984;311(20):1281–6.

    Google Scholar 

  16. Smith Jr JA, Lange PH, Janknegt RA, Abbou CC, deGery A. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol. 1997;157(4):1329–34.

    PubMed  Google Scholar 

  17. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419–24.

    PubMed  CAS  Google Scholar 

  18. Eisenberger MA, Crawford ED, Wolf M, et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol. 1994;21(5):613–9.

    PubMed  CAS  Google Scholar 

  19. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61(1):195–202.

    PubMed  CAS  Google Scholar 

  20. Mulders PF, Dijkman GA, Fernandez del Moral P, Theeuwes AG, Debruyne FM. Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. Cancer. 1990;65(12):2758–61.

    PubMed  CAS  Google Scholar 

  21. de Voogt HJ, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH, de Pauw M. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. J Urol. 1989;141(4):883–8.

    PubMed  Google Scholar 

  22. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA. 1991;265(5):618–21.

    PubMed  CAS  Google Scholar 

  23. Imamoto T, Suzuki H, Akakura K, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J. 2001;48(5):573–8.

    PubMed  CAS  Google Scholar 

  24. Matzkin H, Perito PE, Soloway MS. Prognostic factors in metastatic prostate cancer. Cancer. 1993;72(12 Suppl):3788–92.

    PubMed  CAS  Google Scholar 

  25. Ross RW, Xie W, Regan MM, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008;112(6):1247–53.

    PubMed  Google Scholar 

  26. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169(1):164–9.

    PubMed  CAS  Google Scholar 

  27. Choueiri TK, Xie W, D’Amico AV, et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009;115(5):981–7.

    PubMed  CAS  Google Scholar 

  28. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24(24):3984–90.

    PubMed  Google Scholar 

  29. Sylvester J, Grimm P, Blasco J, et al. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States. Urology. 2001;58(2 Suppl 1):65–70.

    PubMed  CAS  Google Scholar 

  30. Gee WF, Holtgrewe HL, Albertsen PC, et al. Practice trends in the diagnosis and management of prostate cancer in the United States. J Urol. 1995;154(1): 207–8.

    PubMed  CAS  Google Scholar 

  31. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients’ choice of treatment in stage D prostate cancer. Urology. 1989;33(5 Suppl):57–62.

    PubMed  CAS  Google Scholar 

  32. Greenstein A, Plymate SR, Katz PG. Visually stimulated erection in castrated men. J Urol. 1995;153(3 Pt 1): 650–2.

    PubMed  CAS  Google Scholar 

  33. Bollack C, Rougeron G. Hormonal therapy trials in prostatic cancer. An EORTC Genitourinary Group study. Am J Clin Oncol. 1988;11 Suppl 2:S156–9.

    PubMed  Google Scholar 

  34. Schally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971;43(2):393–9.

    PubMed  CAS  Google Scholar 

  35. Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA. 1982;79(5): 1658–62.

    PubMed  CAS  Google Scholar 

  36. Schally AV, Coy DH, Arimura A. LH-RH agonists and antagonists. Int J Gynaecol Obstet. 1980;18(5):318–24.

    PubMed  CAS  Google Scholar 

  37. Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev. 1986;7(1): 44–66.

    PubMed  CAS  Google Scholar 

  38. Waxman J, Man A, Hendry WF, et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotropin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed). 1985;291(6506):1387–8.

    CAS  Google Scholar 

  39. Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol. 1990;144(6):1479–80.

    PubMed  CAS  Google Scholar 

  40. Labrie F, Dupont A, Belanger A, Lachance R. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol. 1987;138(4): 804–6.

    PubMed  CAS  Google Scholar 

  41. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132(7):566–77.

    PubMed  CAS  Google Scholar 

  42. Soloway MS, Chodak G, Vogelzang NJ, et al. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group. Urology. 1991;37(1):46–51.

    PubMed  CAS  Google Scholar 

  43. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995;46(2):220–6.

    PubMed  CAS  Google Scholar 

  44. Turkes AO, Peeling WB, Griffiths K. Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group. J Steroid Biochem. 1987;27(1–3):543–9.

    PubMed  CAS  Google Scholar 

  45. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991;67(5):502–8.

    PubMed  CAS  Google Scholar 

  46. Fowler JE, Flanagan M, Gleason DM, Klimberg IW, Gottesman JE, Sharifi R. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology. 2000;55(5): 639–42.

    PubMed  CAS  Google Scholar 

  47. Fowler Jr JE, Gottesman JE, Reid CF, Andriole Jr GL, Soloway MS. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol. 2000;164(3 Pt 1):730–4.

    PubMed  CAS  Google Scholar 

  48. Millar JL. Triptorelin approved for prostate cancer treatment. Am J Health Syst Pharm. 2000;57(15): 1386.

    PubMed  CAS  Google Scholar 

  49. Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003;92(3):226–31.

    PubMed  CAS  Google Scholar 

  50. McLeod D, Zinner N, Tomera K, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology. 2001;58(5):756–61.

    PubMed  CAS  Google Scholar 

  51. Trachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 2002;167(4): 1670–4.

    PubMed  CAS  Google Scholar 

  52. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531–8.

    PubMed  CAS  Google Scholar 

  53. Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing Degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010;57(5):836–42.

    PubMed  Google Scholar 

  54. Denis L. Prostate cancer. Primary hormonal treatment. Cancer. 1993;71(3 Suppl):1050–8.

    PubMed  CAS  Google Scholar 

  55. Geller J. Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma. Urol Clin North Am. 1991;18(1):83–91.

    PubMed  CAS  Google Scholar 

  56. Crawford ED, Nabors WL. Total androgen ablation: American experience. Urol Clin North Am. 1991;18(1):55–63.

    PubMed  CAS  Google Scholar 

  57. Kennealey GT, Furr BJ. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma. Urol Clin North Am. 1991;18(1):99–110.

    PubMed  CAS  Google Scholar 

  58. Fleshner NE, Fair WR. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol. 1996;78(6): 907–10.

    PubMed  CAS  Google Scholar 

  59. Brufsky A, Fontaine-Rothe P, Berlane K, et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology. 1997;49(6):913–20.

    PubMed  CAS  Google Scholar 

  60. Oh WK, Manola J, Bittmann L, et al. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology. 2003;62(1):99–104.

    PubMed  Google Scholar 

  61. Chang A, Yeap B, Davis T, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol. 1996;14(8):2250–7.

    PubMed  CAS  Google Scholar 

  62. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology. 1996;47(1A Suppl):38–43; discussion 48–53.

    Google Scholar 

  63. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33(5):447–56.

    PubMed  CAS  Google Scholar 

  64. Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol. 1999;17(7):2027–38.

    PubMed  CAS  Google Scholar 

  65. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol. 2000;164(5): 1579–82.

    PubMed  CAS  Google Scholar 

  66. Boccon-Gibod L, Fournier G, Bottet P, et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol. 1997;32(4):391–5; discussion 395–6.

    Google Scholar 

  67. Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol. 2008;8(4): 449–57.

    PubMed  CAS  Google Scholar 

  68. Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. J Urol. 1984;132(1):61–3.

    PubMed  CAS  Google Scholar 

  69. Pont A. Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma. J Urol. 1987;137(5):902–4.

    PubMed  CAS  Google Scholar 

  70. Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982;142(12):2137–40.

    PubMed  CAS  Google Scholar 

  71. Sanford EJ, Drago JR, Rohner Jr TJ, Santen R, Lipton A. Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. J Urol. 1976;115(2):170–4.

    PubMed  CAS  Google Scholar 

  72. Drago JR, Santen RJ, Lipton A, et al. Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer. 1984;53(7):1447–50.

    PubMed  CAS  Google Scholar 

  73. Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer. 2009;100(5):671–5.

    PubMed  CAS  Google Scholar 

  74. Herbst WP. Effects of estradiol diproprionate and diethylstilbestrol on malignant prostatic tissue. Trans Am Assoc Genitourin Surg. 1941;34:195.

    Google Scholar 

  75. Landstrom M, Eklov S, Colosetti P, et al. Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-beta 1 and its type-I and type-II receptors. Int J Cancer. 1996;67(4):573–9.

    PubMed  CAS  Google Scholar 

  76. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988;7:165–70.

    PubMed  Google Scholar 

  77. The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet. 1967;124(5):1011–7.

    Google Scholar 

  78. Robinson MR, Thomas BS. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J. 1971;4(5784):391–4.

    PubMed  CAS  Google Scholar 

  79. Pomerantz M, Manola J, Taplin ME, et al. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007;177(6):2146–50.

    PubMed  CAS  Google Scholar 

  80. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer—forward to the past? J Urol. 2003;169(5):1735–7.

    PubMed  CAS  Google Scholar 

  81. da Silva FC, Reis E, Costa T, Denis L. Quality of life in patients with prostatic cancer. A feasibility study. The Members of Quality of Life Committee of the EORTC Genitourinary Group. Cancer. 1993;71(3 Suppl):1138–42.

    PubMed  Google Scholar 

  82. Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst. 2002;94(6):430–7.

    PubMed  Google Scholar 

  83. Sneeuw KC, Albertsen PC, Aaronson NK. Comparison of patient and spouse assessments of health related quality of life in men with metastatic prostate cancer. J Urol. 2001;165(2):478–82.

    PubMed  CAS  Google Scholar 

  84. Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol. 2001;19(1):72–80.

    PubMed  CAS  Google Scholar 

  85. Kouriefs C, Georgiou M, Ravi R. Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int. 2002;89(4):379–83.

    PubMed  CAS  Google Scholar 

  86. Charig CR, Rundle JS. Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology. 1989;33(3):175–8.

    PubMed  CAS  Google Scholar 

  87. Frodin T, Alund G, Varenhorst E. Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer. Prostate. 1985;7(2): 203–8.

    PubMed  CAS  Google Scholar 

  88. Sarosdy MF, Schellhammer PF, Soloway MS, et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int. 1999;83(7):801–6.

    PubMed  CAS  Google Scholar 

  89. Parmar H, Edwards L, Phillips RH, Allen L, Lightman SL. Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol. 1987;59(3):248–54.

    PubMed  CAS  Google Scholar 

  90. Bressler LR, Murphy CM, Shevrin DH, Warren RF. Use of clonidine to treat hot flashes secondary to leuprolide or goserelin. Ann Pharmacother. 1993;27(2): 182–5.

    PubMed  CAS  Google Scholar 

  91. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331(6):347–52.

    PubMed  CAS  Google Scholar 

  92. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002;77(11):1207–18.

    PubMed  CAS  Google Scholar 

  93. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64.

    PubMed  CAS  Google Scholar 

  94. Galvao DA, Taaffe DR, Spry N, Newton RU. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(4): 340–6.

    PubMed  CAS  Google Scholar 

  95. Adami S. Bisphosphonates in prostate carcinoma. Cancer. 1997;80(8 Suppl):1674–9.

    PubMed  CAS  Google Scholar 

  96. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol. 1998;16(3): 1218–25.

    PubMed  CAS  Google Scholar 

  97. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2002;167(5):1952–6.

    PubMed  CAS  Google Scholar 

  98. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol. 2001;166(6):2023–31.

    PubMed  CAS  Google Scholar 

  99. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer. 2001;92(6):1444–50.

    PubMed  CAS  Google Scholar 

  100. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948–55.

    PubMed  CAS  Google Scholar 

  101. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008–12.

    PubMed  CAS  Google Scholar 

  102. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate ­cancer. J Clin Oncol. 2007;25(9):1038–42.

    PubMed  CAS  Google Scholar 

  103. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146(6):416–24.

    PubMed  Google Scholar 

  104. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19): 1458–68.

    PubMed  CAS  Google Scholar 

  105. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(8):3841–6.

    PubMed  CAS  Google Scholar 

  106. Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008;179(1):152–5.

    PubMed  CAS  Google Scholar 

  107. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55.

    PubMed  CAS  Google Scholar 

  108. Fizazi K, Carducci MA, Smith MR, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2010;28(18 Suppl):LBA4507.

    Google Scholar 

  109. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79(6):933–41.

    PubMed  CAS  Google Scholar 

  110. Cella D, Bron D. The effect of Epoetin alfa on quality of life in anemic cancer patients. Cancer Pract. 1999;7(4):177–82.

    PubMed  CAS  Google Scholar 

  111. Gordon MS. Managing anemia in the cancer patient: old problems, future solutions. Oncologist. 2002;7(4):331–41.

    PubMed  Google Scholar 

  112. Pirker R, Smith R. Darbepoietin alfa: potential role in managing anemia in cancer patients. Expert Rev Anticancer Ther. 2002;2(4):377–84.

    PubMed  CAS  Google Scholar 

  113. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoietin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–24.

    PubMed  CAS  Google Scholar 

  114. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoietin for patients with cancer—meta-­analysis based on individual patient data. Cochrane Database Syst Rev. 2009(3):CD007303.

    Google Scholar 

  115. Kintzel PE, Chase SL, Schultz LM, O’Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008;28(12):1511–22.

    PubMed  CAS  Google Scholar 

  116. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–83.

    PubMed  Google Scholar 

  117. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603.

    PubMed  CAS  Google Scholar 

  118. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 2002;95(10):2136–44.

    PubMed  Google Scholar 

  119. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261–7.

    PubMed  CAS  Google Scholar 

  120. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005;104(8):1633–7.

    PubMed  CAS  Google Scholar 

  121. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–39.

    PubMed  Google Scholar 

  122. Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab. 1988;66(2):314–22.

    PubMed  CAS  Google Scholar 

  123. Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol. 1995;154(1):100–4.

    PubMed  CAS  Google Scholar 

  124. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res. 2006;18(5):494–8.

    PubMed  CAS  Google Scholar 

  125. Smith MR, Malkowicz SB, Chu F, et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol. 2008;26(11):1824–9.

    PubMed  CAS  Google Scholar 

  126. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2):195–201.

    CAS  Google Scholar 

  127. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91(4): 1305–8.

    PubMed  CAS  Google Scholar 

  128. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27): 4448–56.

    PubMed  CAS  Google Scholar 

  129. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3):581–8.

    PubMed  CAS  Google Scholar 

  130. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493–500.

    PubMed  CAS  Google Scholar 

  131. Galvao DA, Spry N, Taaffe DR, et al. A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer. 2009;9:419.

    PubMed  Google Scholar 

  132. Huggins C, Scott WW. Bilateral adrenalectomy in prostatic cancer. Ann Surg. 1945;122:1031.

    Google Scholar 

  133. Bertagna C, De Gery A, Hucher M, Francois JP, Zanirato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol. 1994;73(4):396–402.

    PubMed  CAS  Google Scholar 

  134. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol. 1998;33(2):144–51.

    PubMed  CAS  Google Scholar 

  135. Janknegt RA, Abbou CC, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol. 1993;149(1):77–82; discussion 83.

    Google Scholar 

  136. Caubet JF, Tosteson TD, Dong EW, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology. 1997;49(1):71–8.

    PubMed  CAS  Google Scholar 

  137. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339(15):1036–42.

    PubMed  CAS  Google Scholar 

  138. Beland G, Elhilali M, Fradet Y, et al. Total androgen ablation: Canadian experience. Urol Clin North Am. 1991;18(1):75–82.

    PubMed  CAS  Google Scholar 

  139. Fourcade RO, Cariou G, Coloby P, et al. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study. Eur Urol. 1990;18 Suppl 3:45–7.

    PubMed  Google Scholar 

  140. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet. 1995;346(8970): 265–9.

    Google Scholar 

  141. Agency for Healthcare Policy and Research. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess. 1999;4: 1–246.

    Google Scholar 

  142. Lukka H, Waldron T, Klotz L, Winquist E, Trachtenberg J. Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review. Curr Oncol. 2006;13(3):81–93.

    PubMed  CAS  Google Scholar 

  143. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst. 2000;92(21):1731–9.

    PubMed  CAS  Google Scholar 

  144. Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55(6):1269–77.

    PubMed  CAS  Google Scholar 

  145. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010;57(1):49–59.

    PubMed  CAS  Google Scholar 

  146. Jordan Jr WP, Blackard CE, Byar DP. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J. 1977;70(12):1411–3.

    PubMed  Google Scholar 

  147. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer. 1973;32(5):1126–30.

    PubMed  CAS  Google Scholar 

  148. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997;79(2):235–46.

    Google Scholar 

  149. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. 2002(1):CD003506.

    Google Scholar 

  150. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5.

    PubMed  CAS  Google Scholar 

  151. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    PubMed  CAS  Google Scholar 

  152. De Bono JS, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). J Clin Oncol. 2010;28(15 Suppl):4508.

    Google Scholar 

  153. Osborne CK, Blumenstein B, Crawford ED, et al. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol. 1990;8(10):1675–82.

    PubMed  CAS  Google Scholar 

  154. Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol. 2004;11(2):103–9.

    PubMed  CAS  Google Scholar 

  155. Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008;26(36):5936–42.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Texas Oncology, Charles A. Sammons Cancer Center, Baylor University Medical Center, 3535 Worth Street, Dallas, TX, 75246, USA

    C. Lance Cowey & Thomas E. Hutson

Authors
  1. C. Lance Cowey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas E. Hutson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas E. Hutson .

Editor information

Editors and Affiliations

  1. , Glickman Urological and Kidney, Cleveland Clinic, 9500 Euclid Ave, Cleveland, 44195, Ohio, USA

    Eric A. Klein

  2. Cleveland Clinic, Cleveland Clinic Lerner College of Medic, Department of Regional Urology, at Case Western Reserve, Cleveland, 44195, Ohio, USA

    J. Stephen Jones

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Cowey, C.L., Hutson, T.E. (2012). Management of Newly Diagnosed Metastatic Disease. In: Klein, E., Jones, J. (eds) Management of Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-259-9_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-259-9_22

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-258-2

  • Online ISBN: 978-1-60761-259-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation